Clinical trial
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
NCT00329550 · UCB Japan Co. Ltd., Industry · Completed
Key facts
| NCT number | NCT00329550 |
|---|---|
| Title | Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease |
| Official title | A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until… |
| Lead sponsor | UCB Japan Co. Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Certolizumab pegol (CZP) |
| Enrollment | 40 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 24, 2006 |
| Last update posted | Mar 18, 2015 |
| Countries | Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: